Cited by 34Smoking Behavior and CessationSubstance Abuse Treatment and OutcomesNicotinic Acetylcholine Receptors Study

Addressing the evidence for FDA nicotine replacement therapy label changes: a policy statement of the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco

Open access
Fucito, L. M., Bars, M. P., Forray, A., Rojewski, A. M., Shiffman, S., Selby, P., West, R., Foulds, J. +2 more·2014·Nicotine & Tobacco Research

Abstract

Cigarette smoking creates a substantial public health burden. Identifying new, effective smoking cessation interventions that optimize existing interventions and promoting effective use of approved medications is a priority. When used as directed, nicotine replacement therapy (NRT) aids smoking cessation, but there is opportunity for improving its effectiveness. Until recently, NRT use guidelines advised smokers to begin using NRT on their quit date, only to use 1 NRT formulation at a time, to refrain from using NRT while smoking, and to stop NRT within 3 months regardless of progress. The Food and Drug Administration (FDA) issued a recent announcement allowing for NRT labeling changes with applications from pharmaceutical companies for such changes, and we applaud this decision. Nevertheless, additional revisions are warranted by current research. There is robust evidence that combining a longer-acting form (e.g., patch) with a shorter-acting form (e.g., lozenge) is more effective than NRT monotherapy and is safe. Moreover, extant evidence suggests that NRT use prior to a quit attempt or for smoking reduction as part of a quit attempt is safe and as effective as starting NRT on quit date. Specifically, prequit nicotine patch increases quit rates and may engage additional recalcitrant smokers. Last, NRT use longer than 3 months is safe and may be beneficial for relapse prevention in some smokers. This report summarizes the FDA announcement, reviews the evidence for further revisions to current FDA NRT guidelines, and makes recommendations for over-the-counter (OTC) NRT labeling to allow for (1) combined use of faster-acting NRT medications with nicotine patch, (2) nicotine patch use prior to quit date or NRT for smoking reduction as part of a quit attempt, and (3) prolonged NRT for up to 6 months without healthcare provider consultation.

Integrity signals

Registry

Crossref · 10.1093/ntr/ntu087

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Fucito, L. M., Bars, M. P., Forray, A., Rojewski, A. M., Shiffman, S., Selby, P., West, R., Foulds, J., Toll, B. A., & Writing Committee for the SRNT Policy and Treatment Networks
Affiliations
  • Yale University (US)
  • New York City Fire Department (US)
  • University of Pittsburgh (US)
  • Centre for Addiction and Mental Health (CA)
  • University College London (GB)
  • Pennsylvania State University (US)
  • Yale Cancer Center (US)
Venue
Nicotine & Tobacco Research
Published
2014-06-11
Volume
16
Issue
7
Pages
909-914
ISSN
  • 1462-2203 (ISSN-L)
  • 1469-994X
OpenAlex
W2091559396
Cited by
34
References
49
Citations by year
2025: 1 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 3 · 2019: 2 · 2018: 2 · 2017: 1 · 2016: 7 · 2015: 8 · 2014: 3
FWCI
4.21
Type
journal article
Language
en
Open access
Locations
  • Nicotine & Tobacco Research (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Cancer Research UK (14135)
  • Medical Research Council (MR/K023195/1)
  • Economic and Social Research Council (ES/G007489/1)
  • National Institute on Alcohol Abuse and Alcoholism (K23AA020000)
  • National Institute on Drug Abuse (P50DA036107)
  • National Cancer Institute (P50CA196530)
Topics
  • Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
Keywords
nicotine replacement therapy, smoking cessation, nicotine patch, nicotine lozenges, smoking reduction, relapse prevention, over-the-counter nicotine products
MeSH terms
Administration, Cutaneous, Nonprescription Drugs, Health Policy, Nicotine, Smoking, United States, United States Food and Drug Administration, Randomized Controlled Trials as Topic, Smoking Cessation, Guidelines as Topic, Tobacco Use Cessation Devices

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review